Solasia Gains Global Rights to Oncology Drug from Ziopharm

Solasia Pharma of Tokyo has amended its agreement with Ziopharm Oncology of Boston for darinaparsin, a novel treatment for leukemia. In 2011, Solasia in-licensed rights to darinaparsin for Japan, China and other Asia-Pacific countries. With the new agreement, Solasia has global rights to the drug. The revised agreement calls for Solasia to pay Ziopharm up to $72.2 million in milestones, a royalty on net sales and a percentage of any sublicense revenues. Solasia has already filed to begin clinical trials of darinaparsin in China. More details.... Stock Symbol: (NSDQ: ZIOP) Share this with colleagues: // //